Madrigal Pharmaceuticals

Madrigal Pharmaceuticals

MDGL· Manufacturing· Fiscal year ends in December

CEO pay in FY2025Stock +88.7% in FY2025

Bill Sibold is the CEO of Madrigal Pharmaceuticals and was paid $19.2M in FY2025 (Dec), up 57%.

Pay$100 in the stock at the end of FY22 → $201
CEO pay is from each Madrigal Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Executives6

See all
  1. 1Bill SiboldFY2025
  2. 2David Soergel, M.D.FY2025
  3. 3Rebecca Taub, M.D.FY2025
  4. 4Mardi C. DierFY2025
  5. 5Carole HuntsmanFY2025
  6. 6Shannon KelleyFY2025

Named executives and their total pay, from the Summary Compensation Table of the latest proxy.

Pay

See all

Madrigal Pharmaceuticals paid its 6 named executives $52.0M in total in FY2025 (Dec). CEO Bill Sibold was paid $19.2M of that.

Name
Bill SiboldPresident and Chief Executive Officer
David Soergel, M.D.Executive Vice President and Chief Medical OfficerNot disclosedNot disclosed
Rebecca Taub, M.D.Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer
Mardi C. DierExecutive Vice President and Chief Financial OfficerNot disclosed
Carole HuntsmanExecutive Vice President and Chief Commercial Officer
Shannon KelleyExecutive Vice President and Chief Legal CounselNot disclosed

of each named executive, from the Summary Compensation Table of each proxy.

Peers16

See all

The FY2025 (Dec) proxy of Madrigal Pharmaceuticals names 16 peer companies for pay. Among Madrigal Pharmaceuticals and these peers, CEO pay was 3rd highest of 11 and total shareholder return was the highest of 11.

3rd highest of 11in Madrigal Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:

$6.9M$33.2M

1st highest of 11in Madrigal Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:

$17$524

The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.

Board3

See all
  • Julian C. BakerChair · 2 yr on the boardIndependentNominating and Governance (Chair)—Paid as an executive
  • Rebecca Taub, M.D.Director · 9 yr on the boardNot independent—Paid as an executive
  • Bill SiboldDirector · 2 yr on the boardNot independent—Paid as an executive

The board of the latest proxy (FY2025).

Activity

  1. Pay
    Madrigal Pharmaceuticals CEO pay rose 57% to $19.2M. The stock rose 89% in FY2025 (Dec).
    DEF 14A
  2. Pay
    Madrigal Pharmaceuticals Executive Vice President and Chief Legal Counsel pay rose 11% to $5.2M. The stock rose 89% in FY2025 (Dec).
    DEF 14A
  3. Pay
    Madrigal Pharmaceuticals Division head pay rose 15% to $6.9M. The stock rose 89% in FY2025 (Dec).
    DEF 14A
  4. Pay
    Madrigal Pharmaceuticals CFO pay fell 30% to $6.1M. The stock rose 89% in FY2025 (Dec).
    DEF 14A
  5. Pay
    Madrigal Pharmaceuticals Division head pay rose 38% to $5.4M. The stock rose 89% in FY2025 (Dec).
    DEF 14A
  6. Pay
    Madrigal Pharmaceuticals CEO pay fell 62% to $12.2M. The stock rose 33% in FY2024 (Dec).
    DEF 14A
  7. Pay
    Madrigal Pharmaceuticals Division head pay fell 14% to $6.0M. The stock rose 33% in FY2024 (Dec).
    DEF 14A
  8. Pay
    Madrigal Pharmaceuticals Division head pay rose 26% to $3.9M. The stock rose 33% in FY2024 (Dec).
    DEF 14A
  9. Pay
    Madrigal Pharmaceuticals General counsel pay fell 19% to $4.3M. The stock rose 33% in FY2024 (Dec).
    DEF 14A
  10. Pay
    Madrigal Pharmaceuticals General counsel pay rose 39% to $4.8M. The stock rose 243% in FY2022 (Dec).
    DEF 14A
  11. Pay
    Madrigal Pharmaceuticals Former CFO pay fell 51% to $3.5M. The stock rose 243% in FY2022 (Dec).
    DEF 14A
  12. Pay
    Madrigal Pharmaceuticals Division head pay rose 110% to $7.4M. The stock fell 20% in FY2023 (Dec).
    DEF 14A
  13. Pay
    Madrigal Pharmaceuticals Division head pay rose 27% to $3.5M. The stock rose 243% in FY2022 (Dec).
    DEF 14A
  14. Pay
    Madrigal Pharmaceuticals Division head pay rose 49% to $6.9M. The stock fell 20% in FY2023 (Dec).
    DEF 14A
  15. Pay
    Madrigal Pharmaceuticals Director pay rose 77% to $9.6M. The stock fell 20% in FY2023 (Dec).
    DEF 14A
  16. Pay
    Madrigal Pharmaceuticals General counsel pay rose 11% to $5.3M. The stock fell 20% in FY2023 (Dec).
    DEF 14A
  17. Pay
    Madrigal Pharmaceuticals Former CFO pay rose 51% to $5.3M. The stock fell 20% in FY2023 (Dec).
    DEF 14A
  18. Board
    Julian C. Baker joined the board of Madrigal Pharmaceuticals. Julian C. Baker now sits on 5 public boards.
    3

Filings6

See all
Proxy statementDEF 14AApr 28, 2026FY2025
Annual report10-KFeb 19, 2026FY2025
Proxy statementDEF 14AApr 29, 2025FY2024
Annual report10-KFeb 26, 2025FY2024
Proxy statementDEF 14AApr 29, 2024FY2023
Annual report10-KFeb 28, 2024FY2023
For the press:Download CSVDownload PNGHow to use our data